why choose us

First received: February 08, 2023

Clinical Trial: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Study Status: Completed

Recruit Status: RECRUITING

Condition: Ulcerative Colitis

Study Type: INTERVENTIONAL


Official Title: A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Trea

Brief Summary: A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab.The study will have 4 periods and will last for 36 weeks.

Read more